Menu Content/Inhalt
Search  
Home
Debio 025

Debio 025 (alisporivir) is the first in a new class of drugs called cyclophilin inhibitors, which could become part of the future standard of care for hepatitis C. Debio 025 has a lower potential for resistance selection. Debiopharm obtained positive efficacy results of a phase IIa study with Debio 025.
Debio 025 has been shown to have a potent inhibitory effect on hepatitis C virus (HCV) replication when used alone or in combination with Interferon (IFN).
The product is currently in phase IIb for the treatment of hepatitis C.
Debio 025 has been licenced to Novartis for the entire world except Japan.

Press Releases

09-Feb-2010
Debiopharm Group™ grants an exclusive licence for the development, manufacture and commercialisation of Debio 025 - A potent, first-in-class antiviral agent for the treatment of Hepatitis C -
30-Apr-2009
Clinical Update – Debio 025 in Hepatitis C - Debiopharm starts phase IIb study after record time patient randomisation
28-Apr-2009
Clinical Update – Debio 025 in Hepatitis C - Debiopharm presents promising phase IIa results showing potent antiviral activity
23-Jan-2009
Clinical Update – Debio 025 in Hepatitis C - Debiopharm starts phase IIb triple therapy study, a promising therapeutic avenue
28-Apr-2008
Clinical Update – Debio 025 in Hepatitis C - Presentation of Phase IIa Efficacy Results
-> All Press Releases

Publications

11-Jun-2009
The cyclophilin inhibitor Debio 025 normalizes mitochondrial function, muslce apoptosis and ultrastructural defects in Col6a1-/- mypathic mice
08-May-2009
The Cyclophilin Inhibitor Debio 025 Combined with PEG IFNα2a Significantly Reduces Viral Load in Teatment-Naïve Hepatitis C Patients
02-Feb-2009
An evaluation of the cyclophilin inhibitor Debio 025 and its potential as a treatment for chronic hepatitis C
22-Dec-2008
Debio 025, a cyclophilin binding molecule, is highly efficient in clearing HCV replicon containing cells, alone or when combined with STAT-C inhibitors
16-Sep-2008
Comparative in vitro anti-hepatitis C virus activity of a selected series of polymerase, protease and helicase inhibitors
-> All Publications